The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Inhibitory Phosphorylation of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium
Open accessAbstract
Glycogen synthase kinase-3 (GSK-3) is a critical, negative regulator of diverse signaling pathways. Lithium is a direct inhibitor of GSK-3 and has been widely used to test the putative role of GSK-3 in multiple settings. However, lithium also inhibits other targets, including inositol monophosphatase and structurally related phosphomonoesterases, and thus additional approaches are needed to attribute a given biological effect of lithium to a specific target. For example, lithium is known to increase the inhibitory N-terminal phosphorylation of GSK-3, but the target of lithium responsible for this indirect regulation has not been identified. We have characterized a short peptide derived from the GSK-3 interaction domain of Axin that potently inhibits GSK-3 activity in vitro and in mammalian cells and robustly activates Wnt-dependent transcription, mimicking lithium action. We show here, using the GSK-3 interaction domain peptide, as well as small molecule inhibitors of GSK-3, that lithium induces GSK-3 N-terminal phosphorylation through direct inhibition of GSK-3 itself. Reduction of GSK-3 protein levels, either by RNA interference or by disruption of the mouse GSK-3beta gene, causes increased N-terminal phosphorylation of GSK-3, confirming that GSK-3 regulates its own phosphorylation status. Finally, evidence is presented that N-terminal phosphorylation of GSK-3 can be regulated by the GSK-3-dependent protein phosphatase-1.inhibitor-2 complex.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC −/− Colon Carcinoma
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., & Clevers, H. (1997) · Science · doi:10.1126/science.275.5307.1784 · Cited by 2,905
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301
Self-citationBoulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radzlejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H., & Yancopoulos, G. D. (1991) · Cell · doi:10.1016/0092-8674(91)90098-j · Cited by 1,897
XTcf-3 Transcription Factor Mediates β-Catenin-Induced Axis Formation in Xenopus Embryos
Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., Korinek, V., Roose, J., Destrée, O., & Clevers, H. (1996) · Cell · doi:10.1016/s0092-8674(00)80112-9 · Cited by 1,824
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758
Self-citationLITHIUM SALTS IN THE TREATMENT OF PSYCHOTIC EXCITEMENT
Cade, J. F. J. (1949) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb36912.x · Cited by 1,463
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M.-S., Jin, O., & Woodgett, J. R. (2000) · Nature · doi:10.1038/35017574 · Cited by 1,393
Cited by
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Beaulieu, J.-M., Sotnikova, T. D., Yao, W.-D., Kockeritz, L., Woodgett, J. R., Gainetdinov, R. R., & Caron, M. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307921101 · Cited by 793
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709
Bioactive Nanoengineered Hydrogels for Bone Tissue Engineering: A Growth-Factor-Free Approach
Xavier, J. R., Thakur, T., Desai, P., Jaiswal, M. K., Sears, N., Cosgriff-Hernandez, E., Kaunas, R., & Gaharwar, A. K. (2015) · ACS Nano · doi:10.1021/nn507488s · Cited by 653
Gong, C.-X., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 644
Pharmacological inhibitors of glycogen synthase kinase 3
MEIJER, L., FLAJOLET, M., & GREENGARD, P. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.07.006 · Cited by 584
Nuclear Receptor Rev-erbα Is a Critical Lithium-Sensitive Component of the Circadian Clock
Yin, L., Wang, J., Klein, P. S., & Lazar, M. A. (2006) · Science · doi:10.1126/science.1121613 · Cited by 556
Self-citationLithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes
Jope, R. S. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00206-2 · Cited by 500
Both the Establishment and the Maintenance of Neuronal Polarity Require Active Mechanisms
Jiang, H., Guo, W., Liang, X., & Rao, Y. (2005) · Cell · doi:10.1016/j.cell.2004.12.033 · Cited by 494
Zeng, X., Huang, H., Tamai, K., Zhang, X., Harada, Y., Yokota, C., Almeida, K., Wang, J., Doble, B., Woodgett, J., et al. (2008) · Development · doi:10.1242/dev.013540 · Cited by 492
GSK-3: Functional Insights from Cell Biology and Animal Models
Kaidanovich-Beilin, O., & Woodgett, J. R. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00040 · Cited by 485
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity
Trivedi, C. M., Luo, Y., Yin, Z., Zhang, M., Zhu, W., Wang, T., Floss, T., Goettlicher, M., Noppinger, P. R., Wurst, W., et al. (2007) · Nature Medicine · doi:10.1038/nm1552 · Cited by 468
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459
“Furthermore, amplification mechanisms involving Ser9 phosphorylation and dephosphorylation that affect both inhibitio”
BackgroundThe Akt–GSK-3 signaling cascade in the actions of dopamine
Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.02.006 · Cited by 419
Mitochondrial membrane permeabilization in neuronal injury
Galluzzi, L., Blomgren, K., & Kroemer, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2665 · Cited by 418
O'Brien, W. T., Harper, A. D., Jové, F., Woodgett, J. R., Maretto, S., Piccolo, S., & Klein, P. S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4753-03.2004 · Cited by 415
Self-citationTherapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Gaharwar, A. K., Cross, L. M., Peak, C. W., Gold, K., Carrow, J. K., Brokesh, A., & Singh, K. A. (2019) · Advanced Materials · doi:10.1002/adma.201900332 · Cited by 402
Chen, Y., Whetstone, H. C., Lin, A. C., Nadesan, P., Wei, Q., Poon, R., & Alman, B. A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040249 · Cited by 391
GSK-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder
Valvezan, A. J., & Klein, P. S. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00001 · Cited by 382
Self-citationGlycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs
Gould, T. D., & Manji, H. K. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300731 · Cited by 375
A Role for Glycogen Synthase Kinase-3β in the Mammalian Circadian Clock
Iitaka, C., Miyazaki, K., Akaike, T., & Ishida, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503526200 · Cited by 373
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
Eldar-Finkelman, H., & Martinez, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00032 · Cited by 354
Ferrer, I., Gomez-Isla, T., Puig, B., Freixes, M., Ribe, E., Dalfo, E., & Avila, J. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772713 · Cited by 304
Targeting protein kinases in central nervous system disorders
Chico, L. K., Van Eldik, L. J., & Watterson, D. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2999 · Cited by 298
Is Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?
Li, X., & Jope, R. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.105 · Cited by 294
Inhibition of GSK3 by lithium, from single molecules to signaling networks
Freland, L., & Beaulieu, J.-M. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00014 · Cited by 269
Serotonin Modulates Circadian Entrainment in Drosophila
Yuan, Q., Lin, F., Zheng, X., & Sehgal, A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.027 · Cited by 261
Tissue-Specific Role of Glycogen Synthase Kinase 3β in Glucose Homeostasis and Insulin Action
Patel, S., Doble, B. W., MacAulay, K., Sinclair, E. M., Drucker, D. J., & Woodgett, J. R. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00763-08 · Cited by 260
Engel, T., Hernández, F., Avila, J., & Lucas, J. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0604-06.2006 · Cited by 260
Phosphorylation of Serine 468 by GSK-3β Negatively Regulates Basal p65 NF-κB Activity
Buss, H., Dörrie, A., Schmitz, M. L., Frank, R., Livingstone, M., Resch, K., & Kracht, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400442200 · Cited by 252
Engel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223
GSK3β and tau protein in Alzheimer's disease and epilepsy
Toral-Rios, D., Pichardo-Rojas, P. S., Alonso-Vanegas, M., & Campos-Peña, V. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00019 · Cited by 158
Basheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02113-z · Cited by 159
Lithium: the pharmacodynamic actions of the amazing ion
Brown, K. M., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312471963 · Cited by 140
Assessment of circadian function in fibroblasts of patients with bipolar disorder
Yang, S., Van Dongen, H. P. A., Wang, K., Berrettini, W., & Bućan, M. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.10 · Cited by 113
Wnt modulation in bone healing
Schupbach, D., Comeau-Gauthier, M., Harvey, E., & Merle, G. (2020) · Bone · doi:10.1016/j.bone.2020.115491 · Cited by 60
Farías, G. G., Godoy, J. A., Hernández, F., Avila, J., Fisher, A., & Inestrosa, N. C. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.016 · Cited by 59
Lin, Y.-C., Kuo, H.-C., Wang, J.-S., & Lin, W.-W. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102739 · Cited by 46
Metadata
- Authors
- Zhang, F., Phiel, C. J., Spece, L., Gurvich, N., & Klein, P. S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-08
- Volume
- 278
- Issue
- 35
- Pages
- 33067-33077
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2038084705
- Cited by
- 435
- References
- 88
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.